Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?

Hiroyuki Ochi, Koji Matsumoto, Kazunari Kondo, Akinori Oki, Reiko Furuta, Yasuo Hirai, Toshiharu Yasugi, Naoyoshi Takatsuka, Hiroo Maeda, Akira Mitsuhashi, Takuma Fujii, Kei Kawana, Tsuyoshi Iwasaka, Nobuo Yaegashi, Yoh Watanabe, Yutaka Nagai, Tomoyuki Kitagawa, Tadahito Kanda, Hiroyuki Yoshikawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To determine the role of neutralizing antibody generated by human papillomavirus (HPV) infections, baseline levels of serum neutralizing antibodies directed against HPV 16 and cervical HPV DNA were determined in 242 unvaccinated women with low-grade cervical abnormalities, who were then monitored by cytology and colposcopy every 4 months. In women infected with HPV 16 (n=42), abnormal cytology persisted longer in those positive for HPV 16-specific neutralizing antibodies at baseline (median time to cytological regression: 23.8 vs. 7.2 months). Progression to cervical precancer (cervical intraepithelial neoplasia grade 3) within 5 years occurred only among women carrying HPV 16-specific neutralizing antibodies (P=0.03, log-rank test). In women infected with types other than HPV 16 (n=200), detection of HPV 16-specific neutralizing antibodies was not correlated with disease outcome. In conclusion, development of specific neutralizing antibodies following natural HPV 16 infection did not favor a better outcome of low-grade cervical lesions induced by HPV 16 or by other types; rather, detection of neutralizing antibodies generated by current infection may reflect viral persistence and thus help identify those who are at high risk of disease progression.

Original languageEnglish
Pages (from-to)1128-1134
Number of pages7
JournalJournal of Medical Virology
Volume84
Issue number7
DOIs
Publication statusPublished - 01-07-2012

Fingerprint

Papillomavirus Infections
Human papillomavirus 16
Neutralizing Antibodies
Antibody Formation
Cell Biology
Colposcopy
Cervical Intraepithelial Neoplasia
Disease Progression
DNA
Infection
Serum

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

Ochi, Hiroyuki ; Matsumoto, Koji ; Kondo, Kazunari ; Oki, Akinori ; Furuta, Reiko ; Hirai, Yasuo ; Yasugi, Toshiharu ; Takatsuka, Naoyoshi ; Maeda, Hiroo ; Mitsuhashi, Akira ; Fujii, Takuma ; Kawana, Kei ; Iwasaka, Tsuyoshi ; Yaegashi, Nobuo ; Watanabe, Yoh ; Nagai, Yutaka ; Kitagawa, Tomoyuki ; Kanda, Tadahito ; Yoshikawa, Hiroyuki. / Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?. In: Journal of Medical Virology. 2012 ; Vol. 84, No. 7. pp. 1128-1134.
@article{ebc633ee5e87428b9a3421baab13a0c7,
title = "Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?",
abstract = "To determine the role of neutralizing antibody generated by human papillomavirus (HPV) infections, baseline levels of serum neutralizing antibodies directed against HPV 16 and cervical HPV DNA were determined in 242 unvaccinated women with low-grade cervical abnormalities, who were then monitored by cytology and colposcopy every 4 months. In women infected with HPV 16 (n=42), abnormal cytology persisted longer in those positive for HPV 16-specific neutralizing antibodies at baseline (median time to cytological regression: 23.8 vs. 7.2 months). Progression to cervical precancer (cervical intraepithelial neoplasia grade 3) within 5 years occurred only among women carrying HPV 16-specific neutralizing antibodies (P=0.03, log-rank test). In women infected with types other than HPV 16 (n=200), detection of HPV 16-specific neutralizing antibodies was not correlated with disease outcome. In conclusion, development of specific neutralizing antibodies following natural HPV 16 infection did not favor a better outcome of low-grade cervical lesions induced by HPV 16 or by other types; rather, detection of neutralizing antibodies generated by current infection may reflect viral persistence and thus help identify those who are at high risk of disease progression.",
author = "Hiroyuki Ochi and Koji Matsumoto and Kazunari Kondo and Akinori Oki and Reiko Furuta and Yasuo Hirai and Toshiharu Yasugi and Naoyoshi Takatsuka and Hiroo Maeda and Akira Mitsuhashi and Takuma Fujii and Kei Kawana and Tsuyoshi Iwasaka and Nobuo Yaegashi and Yoh Watanabe and Yutaka Nagai and Tomoyuki Kitagawa and Tadahito Kanda and Hiroyuki Yoshikawa",
year = "2012",
month = "7",
day = "1",
doi = "10.1002/jmv.23258",
language = "English",
volume = "84",
pages = "1128--1134",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "7",

}

Ochi, H, Matsumoto, K, Kondo, K, Oki, A, Furuta, R, Hirai, Y, Yasugi, T, Takatsuka, N, Maeda, H, Mitsuhashi, A, Fujii, T, Kawana, K, Iwasaka, T, Yaegashi, N, Watanabe, Y, Nagai, Y, Kitagawa, T, Kanda, T & Yoshikawa, H 2012, 'Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?', Journal of Medical Virology, vol. 84, no. 7, pp. 1128-1134. https://doi.org/10.1002/jmv.23258

Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions? / Ochi, Hiroyuki; Matsumoto, Koji; Kondo, Kazunari; Oki, Akinori; Furuta, Reiko; Hirai, Yasuo; Yasugi, Toshiharu; Takatsuka, Naoyoshi; Maeda, Hiroo; Mitsuhashi, Akira; Fujii, Takuma; Kawana, Kei; Iwasaka, Tsuyoshi; Yaegashi, Nobuo; Watanabe, Yoh; Nagai, Yutaka; Kitagawa, Tomoyuki; Kanda, Tadahito; Yoshikawa, Hiroyuki.

In: Journal of Medical Virology, Vol. 84, No. 7, 01.07.2012, p. 1128-1134.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?

AU - Ochi, Hiroyuki

AU - Matsumoto, Koji

AU - Kondo, Kazunari

AU - Oki, Akinori

AU - Furuta, Reiko

AU - Hirai, Yasuo

AU - Yasugi, Toshiharu

AU - Takatsuka, Naoyoshi

AU - Maeda, Hiroo

AU - Mitsuhashi, Akira

AU - Fujii, Takuma

AU - Kawana, Kei

AU - Iwasaka, Tsuyoshi

AU - Yaegashi, Nobuo

AU - Watanabe, Yoh

AU - Nagai, Yutaka

AU - Kitagawa, Tomoyuki

AU - Kanda, Tadahito

AU - Yoshikawa, Hiroyuki

PY - 2012/7/1

Y1 - 2012/7/1

N2 - To determine the role of neutralizing antibody generated by human papillomavirus (HPV) infections, baseline levels of serum neutralizing antibodies directed against HPV 16 and cervical HPV DNA were determined in 242 unvaccinated women with low-grade cervical abnormalities, who were then monitored by cytology and colposcopy every 4 months. In women infected with HPV 16 (n=42), abnormal cytology persisted longer in those positive for HPV 16-specific neutralizing antibodies at baseline (median time to cytological regression: 23.8 vs. 7.2 months). Progression to cervical precancer (cervical intraepithelial neoplasia grade 3) within 5 years occurred only among women carrying HPV 16-specific neutralizing antibodies (P=0.03, log-rank test). In women infected with types other than HPV 16 (n=200), detection of HPV 16-specific neutralizing antibodies was not correlated with disease outcome. In conclusion, development of specific neutralizing antibodies following natural HPV 16 infection did not favor a better outcome of low-grade cervical lesions induced by HPV 16 or by other types; rather, detection of neutralizing antibodies generated by current infection may reflect viral persistence and thus help identify those who are at high risk of disease progression.

AB - To determine the role of neutralizing antibody generated by human papillomavirus (HPV) infections, baseline levels of serum neutralizing antibodies directed against HPV 16 and cervical HPV DNA were determined in 242 unvaccinated women with low-grade cervical abnormalities, who were then monitored by cytology and colposcopy every 4 months. In women infected with HPV 16 (n=42), abnormal cytology persisted longer in those positive for HPV 16-specific neutralizing antibodies at baseline (median time to cytological regression: 23.8 vs. 7.2 months). Progression to cervical precancer (cervical intraepithelial neoplasia grade 3) within 5 years occurred only among women carrying HPV 16-specific neutralizing antibodies (P=0.03, log-rank test). In women infected with types other than HPV 16 (n=200), detection of HPV 16-specific neutralizing antibodies was not correlated with disease outcome. In conclusion, development of specific neutralizing antibodies following natural HPV 16 infection did not favor a better outcome of low-grade cervical lesions induced by HPV 16 or by other types; rather, detection of neutralizing antibodies generated by current infection may reflect viral persistence and thus help identify those who are at high risk of disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84861003542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861003542&partnerID=8YFLogxK

U2 - 10.1002/jmv.23258

DO - 10.1002/jmv.23258

M3 - Article

VL - 84

SP - 1128

EP - 1134

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 7

ER -